BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Janssen, L.P. 

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560-0200  U.S.A.
Phone: 609-730-2000 Fax: 609-730-2323


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

Alkermes plc 





 Company News
Janssen, L.P.'s RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5/20/2009 8:52:04 AM    More...
Janssen, L.P. New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 5/19/2009 11:05:33 AM    More...
FDA Grants Approval for Use of Janssen, L.P.'s RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 5/18/2009 7:22:46 AM    More...
Janssen, L.P. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 12/10/2008 7:32:58 AM    More...
Janssen, L.P. Announces Launch of Authorized Generic for RISPERDAL(R) 7/1/2008 10:27:11 AM    More...
Janssen, L.P. Release: Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2/4/2008 8:10:40 AM    More...
Janssen, L.P. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 10/15/2007 9:25:54 AM    More...
Janssen, L.P. and Johnson and Johnson Pharmaceutical R&D (NJ) Release: FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania 8/22/2007 11:04:34 AM    More...
Janssen, L.P. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant 5/23/2007 11:26:08 AM    More...
FDA Approves New Dose of Janssen, L.P. and Alkermes (ALKS)'s RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment 4/13/2007 9:41:19 AM    More...
12

//-->